Zika vaccine-blocker candidate being tested in animals

By Melissa Fassbender contact

- Last updated on GMT

Human trials may begin as early as July 2016. (Image: iStock)
Human trials may begin as early as July 2016. (Image: iStock)

Related tags: Evolution, Genome, Nervous system

Replikins’ genomic understanding of the Zika and Flaviviruses has led to the development of a trivalent vaccine for Zika, Dengue, and Japanese Encephalitis. 

The company announced its understanding of how the virus gene structures in Zika and closely related Flaviviruses evolves, earlier this week.

According to the company, a trivalent Zika-Dengue-Japanese Encephalitis Replikins Synthetic Blocker-Vaccine™ candidate has been designed and manufactured by Replikins Ltd., and is now being tested.

A Zika Gene Synthetic Replikins Vaccine-Blocker candidate has been formulated and manufactured, and is now in animal trials. Trials in humans may begin as early as July 2016​,” Samuel Bogoch,M.D.,Ph.D., chairman, Replikins Ltd., told Outsourcing-Pharma.com.

The new vaccine candidate is based on findings from Drs. Samuel and Elenore Bogoch of Boston University School of Medicine, the Foundation for Research on the Nervous System, and Replikins Ltd.

Though their research, the doctors found conserved Replikins gene sequences shared by three different Flaviviruses and “a suggestion of transfer​” of Replikins over time between the viruses. (Replikins are a group of peptides, which when increased in concentration in a virus is associated with rapid replication).

The company previously reported in January that sequences in the Zika gene were at the highest levels observed since 1947. The company used its genomic disease surveillance software to analyze the concentration and evolution changes in the genomes.

The company will report results from animal testing of the trivalent vaccine candidate as they become available.

Related news

Show more

Related products

show more

How a clinical metadata repository helps with data

How a clinical metadata repository helps with data

Formedix | 22-Mar-2021 | Technical / White Paper

This article covers the various ways a clinical metadata repository helps with data quality, and in turn, with data quality in the clinical trials process....

Introduction to eLAS®

Introduction to eLAS®

Clinical Ink | 08-Mar-2021 | Product Brochure

Clinical Ink has developed a unique offering — the electronic Lupus Assessment Suite (eLAS®) to address fundamental challenges impacting systemic lupus...

Related suppliers

Follow us


View more